Expression and clinical significance of Cathepsin K and MMPs in invasive non-functioning pituitary adenomas

Hongyan Liu, Saichun Zhang, Ting Wu, Zhaohui Lv, Jianming Ba, Weijun Gu, Yiming MuFrontiers in Oncology 2022 · DOI

TL;DR

This study investigates the expression of specific proteins (CTSK, MMP9, MMP2, TIMP2, PTTG1) in non-functioning pituitary adenomas (NFPAs) to understand their role in tumor invasion and recurrence. They found that CTSK is a potential marker for sphenoid sinus invasion, while MMP9 and MMP2 are associated with cavernous sinus invasion, and CTSK is also linked to a higher risk of tumor relapse.

What Problem Does This Paper Address?

Pituitary adenomas (PAs) are common intracranial tumors. While many are benign and hormone-inactive, some can become locally invasive, infiltrating surrounding structures like the sphenoid sinus (SS) and cavernous sinus (CS). This invasion makes complete surgical removal difficult and increases the risk of recurrence. Understanding the molecular mechanisms behind this invasion is crucial for better diagnosis, prognosis, and treatment. Previous research has implicated matrix metalloproteinases (MMPs) in PA invasion, but the specific roles of various biomarkers in different invasion patterns (SS vs. CS) and their correlation with recurrence remained unclear. This paper aims to fill this gap by examining the expression of CTSK, MMP9, MMP2, TIMP2, and PTTG1 in NFPAs with varying invasion patterns and their association with clinical outcomes.

Methods

The researchers conducted a retrospective cohort study using paraffin-embedded tumor tissues from 174 patients with non-functioning pituitary adenomas (NFPAs). They employed immunohistochemical staining to assess the expression levels of five key protein biomarkers: Cathepsin K (CTSK), Matrix Metalloproteinase-9 (MMP9), Matrix Metalloproteinase-2 (MMP2), Tissue Inhibitor of Metalloproteinases-2 (TIMP2), and Pituitary Tumor Transforming Gene 1 (PTTG1). The intensity and extent of staining were quantified. Statistical analyses, including t-tests, chi-square tests, Pearson correlation, and multiple Cox regression, were used to compare protein expression levels between different invasion groups (SS-invasive, CS-invasive, non-invasive) and to identify factors associated with tumor recurrence.

Datasets

The study utilized a dataset of 174 paraffin-embedded NFPA tumor tissues collected from patients who underwent surgery at the Chinese PLA General Hospital between 2011 and 2018. The tissues were categorized into three groups: PAs invading the sphenoid sinus only (n=44), PAs invading the cavernous sinus only (n=50), and non-invasive PAs (n=80). Clinical data, including patient demographics, tumor characteristics, and postoperative follow-up information, were also collected and analyzed.

Key Insights and Ideas

  • CTSK as a Sphenoid Sinus Invasion Marker: The study's most striking finding is the significantly higher expression of CTSK in pituitary adenomas that invade the sphenoid sinus compared to those invading the cavernous sinus or non-invasive tumors. This suggests CTSK might be a specific indicator of SS invasion.
  • MMP9 and MMP2 for Cavernous Sinus Invasion: Conversely, MMP9 and MMP2 showed higher expression in CS-invasive PAs compared to SS-invasive ones, pointing to their potential role as markers for CS invasion.
  • CTSK's Role in Recurrence: Beyond invasion, CTSK emerged as an independent risk factor for tumor recurrence, alongside subtotal resection, invasion itself, and larger tumor diameter. This highlights CTSK's broader clinical significance in predicting patient outcomes.
  • Complex Interactions: The study also revealed correlations between some of these markers (e.g., positive correlation between MMP9 and MMP2, negative correlations with TIMP2), suggesting intricate molecular pathways are at play in PA invasion.

Key Results

  • CTSK Expression: CTSK levels were significantly higher in SS-invasive PAs (95.57 ± 31.57) compared to CS-invasive PAs (65.29 ± 29.64) (P < 0.001).
  • MMP9 and MMP2 Expression: MMP9 and MMP2 were significantly higher in CS-invasive cases (MMP9: 145.02 ± 49.25; MMP2: 138.67 ± 52.06) than in SS-invasive cases (MMP9: 111.80 ± 51.37; MMP2: 108.30 ± 41.70) (P = 0.002 for both).
  • Recurrence Risk Factors: Multiple Cox regression identified higher CTSK expression (P=0.011), subtotal resection (P<0.001), invasion (P=0.037), and larger tumor diameter (P=0.001) as independent risk factors for recurrence.
  • CTSK and Tumor Size: A strong positive correlation was observed between CTSK expression and tumor size (r=0.671, p<0.001).
  • TIMP2 and PTTG1: No significant differences in TIMP2 and PTTG1 levels were found between CS- and SS-invasive cases.

Limitations and Future Work

The authors acknowledge that this is a retrospective study, which inherently has limitations. They also note that while TIMP2's function is complex and can be both inhibitory and activating for MMPs, its role in PA invasion requires further investigation. Future work suggested by the authors includes exploring the potential of CTSK as a predictor of bone invasion and recurrence in NFPAs in clinical practice. Additionally, they plan to conduct studies on animal models to investigate the function of CTSK inhibitors (CatKi) in SS invasion of PAs.

Summary updated

Abstract

Background Cathepsin K (CTSK) is a protease that degrades type I collagen and extracellular matrix, thereby contributing to bone resorption and tumor invasion. Some pituitary adenomas (PAs) could invade the sphenoid sinus (SS) and cavernous sinus (CS). Purpose This retrospective cohort study aimed to study the expression of tumoral biomarkers (CTSK, MMP9, MMP2, TIMP2, and PTTG1) and evaluate their clinical significance in non-functioning pituitary adenomas (NFPAs) with different invasion patterns. Methods We assessed the expression levels of candidate invasion-specific protein biomarkers CTSK, MMP9, MMP2, TIMP2, and PTTG1 by immunohistochemical staining in paraffin-embedded NFPA tumor tissues. Variations in staining intensity were analyzed in cases with SS and CS invasion and non-invasive NFPAs. Results We found that the levels of CTSK were higher in PA cases with SS invasion than that in PA cases with CS invasion (95.57 ± 31.57 vs. 65.29 ± 29.64, P &amp;lt; 0.001), and the expression of MMP9 and MMP2 was higher in CS-invasive cases than that in SS-invasive cases (145.02 ± 49.25 vs. 111.80 ± 51.37, P = 0.002, and 138.67 ± 52.06 vs. 108.30 ± 41.70, P = 0.002). Multiple Cox regression demonstrated that higher CTSK expression (P=0.011), subtotal resection (P&amp;lt;0.001), invasion (P=0.037), and larger tumor diameter (P=0.001) were independent risk factors for recurrence. A positive correlation was observed between CTSK expression and tumor size (r=0.671, p&amp;lt;0.001). There was no significant difference in TIMP2 and PTTG1 levels between CS-and SS-invasive cases (97.42± 39.80 vs. 102.10± 43.22, P = 0.58 and 13.89 ± 4.59 vs. 12.56 ± 3.96, P = 0.14). Conclusion Our data indicated that CTSK has the potential as a marker for SS invasion of PAs, whereas MMP9 and MMP2 may be markers for CS invasion. And CTSK may play an important role in tumor relapse.
BibTeX
@inproceedings{liu2022expression,
  author = {Hongyan Liu and Saichun Zhang and Ting Wu and Zhaohui Lv and Jianming Ba and Weijun Gu and Yiming Mu},
  title = {{Expression and clinical significance of Cathepsin K and MMPs in invasive non-functioning pituitary adenomas}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.901647},
}
Figure